Literature DB >> 6879483

Prognosis of cryptogenic fibrosing alveolitis.

P Tukiainen, E Taskinen, P Holsti, O Korhola, M Valle.   

Abstract

We have analysed retrospectively 100 consecutive patients with cryptogenic fibrosing alveolitis, who were treated with corticosteroids and followed for at least three years. At the time of diagnosis biopsy specimens were available in 64 cases. The clinical, radiographic, physiological, and histological features and the response to steroid treatment have been correlated with the prognosis. An early objective functional improvement was observed in 30%. Analysis of the survival data (life table and log rank test) showed a longer survival in younger patients and in patients with a shorter duration of symptoms before presentation, less radiographic abnormality, and less impairment of diffusing capacity, but not clearly in patients with more cellular histological appearances. The most favourable prognostic sign seemed to be an early response to steroid treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6879483      PMCID: PMC459556          DOI: 10.1136/thx.38.5.349

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  14 in total

1.  The Hamman-Rich syndrome: review of the literature and analysis of 15 cases.

Authors:  E H RUBIN; R LUBLINER
Journal:  Medicine (Baltimore)       Date:  1957-12       Impact factor: 1.889

2.  A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide.

Authors:  W S BLAKEMORE; R E FORSTER; J W MORTON; C M OGILVIE
Journal:  J Clin Invest       Date:  1957-01       Impact factor: 14.808

3.  The prognosis of cryptogenic fibrosing alveolitis.

Authors:  B H Stack; Y F Choo-Kang; B E Heard
Journal:  Thorax       Date:  1972-09       Impact factor: 9.139

4.  Natural history and treated course of usual and desquamative interstitial pneumonia.

Authors:  C B Carrington; E A Gaensler; R E Coutu; M X FitzGerald; R G Gupta
Journal:  N Engl J Med       Date:  1978-04-13       Impact factor: 91.245

5.  Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features.

Authors:  P H Wright; B E Heard; S J Steel; M Turner-Warwick
Journal:  Br J Dis Chest       Date:  1981-01

6.  Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-08       Impact factor: 9.139

7.  Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-03       Impact factor: 9.139

8.  Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs). Correlation of histology at biopsy with prognosis.

Authors:  J G Scadding; K F Hinson
Journal:  Thorax       Date:  1967-07       Impact factor: 9.139

9.  Cryptogenic fibrosing alveolitis and lung cancer.

Authors:  M Turner-Warwick; M Lebowitz; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  16 in total

Review 1.  Review of cryptogenic fibrosing alveolitis, including current treatment guidelines.

Authors:  S C Bourke; H Clague
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 3.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis.

Authors:  Xueren Li; Shouchun Peng; Luqing Wei; Zhenhua Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

5.  British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.

Authors:  I D Johnston; R J Prescott; J C Chalmers; R M Rudd
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

6.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 7.  Diffuse lung disease: an approach to management.

Authors:  R M du Bois
Journal:  BMJ       Date:  1994-07-16

8.  Rising mortality from cryptogenic fibrosing alveolitis.

Authors:  I Johnston; J Britton; W Kinnear; R Logan
Journal:  BMJ       Date:  1990-11-03

9.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

Review 10.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.